Adenovirus Vectors Based on Human Adenovirus Type 19a Have High Potential for Human Muscle-Directed Gene Therapy

2006 ◽  
Vol 17 (2) ◽  
pp. 193-205 ◽  
Author(s):  
Christian Thirion ◽  
Hanns Lochmüller ◽  
Zsolt Ruzsics ◽  
Marc Boelhauve ◽  
Cornelia König ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Human Adenovirus ◽  
Adenovirus Type ◽  
Human Muscle ◽  
High Potential ◽  
Adenovirus Vectors

Adenovirus Vectors Based on Human Adenovirus Type 19a Have High Potential for Human Muscle-Directed Gene Therapy

2006 ◽  
Vol 0 (0) ◽  
pp. 060123080936007
Author(s):  
Christian Thirion ◽  
Hanns Lochmuller ◽  
Zsolt Ruzsics ◽  
Marc Boelhauve ◽  
Cornelia Konig ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Human Adenovirus ◽  
Adenovirus Type ◽  
Human Muscle ◽  
High Potential ◽  
Adenovirus Vectors

scholarly journals Adenovirus Type 6: Subtle Structural Distinctions from Adenovirus Type 5 Result in Essential Differences in Properties and Perspectives for Gene Therapy

Pharmaceutics ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 1641
Author(s):  
Margarita Romanenko ◽  
Ivan Osipov ◽  
Sergey V. Netesov ◽  
Julia Davydova
Keyword(s):  
Gene Therapy ◽  
Vaccine Development ◽  
Viral Vector ◽  
Human Adenovirus ◽  
Adenovirus Type ◽  
Structural Features ◽  
Blood Proteins ◽  
Multiple Cancer ◽  
Oncolytic Therapy ◽  
Adenovirus Type 5

Adenovirus vectors are the most frequently used agents for gene therapy, including oncolytic therapy and vaccine development. It’s hard to overestimate the value of adenoviruses during the COVID-19 pandemic as to date four out of four approved viral vector-based SARS-CoV-2 vaccines are developed on adenovirus platform. The vast majority of adenoviral vectors are based on the most studied human adenovirus type 5 (HAdV-C5), however, its immunogenicity often hampers the clinical translation of HAdV-C5 vectors. The search of less seroprevalent adenovirus types led to another species C adenovirus, Adenovirus type 6 (HAdV-C6). HAdV-C6 possesses high oncolytic efficacy against multiple cancer types and remarkable ability to induce the immune response towards carrying antigens. Being genetically very close to HAdV-C5, HAdV-C6 differs from HAdV-C5 in structure of the most abundant capsid protein, hexon. This leads to the ability of HAdV-C6 to evade the uptake by Kupffer cells as well as to distinct opsonization by immunoglobulins and other blood proteins, influencing the overall biodistribution of HAdV-C6 after systemic administration. This review describes the structural features of HAdV-C6, its interaction with liver cells and blood factors, summarizes the previous experiences using HAdV-C6, and provides the rationale behind the use of HAdV-C6 for vaccine and anticancer drugs developments.

scholarly journals Human adenovirus type 35 vector for gene therapy of brain cancer: improved transduction and bypass of pre-existing anti-vector immunity in cancer patients

2006 ◽  
Vol 14 (2) ◽  
pp. 211-219 ◽  
Author(s):  
E Brouwer ◽  
M J Havenga ◽  
O Ophorst ◽  
B de Leeuw ◽  
L Gijsbers ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Cancer Patients ◽  
Brain Cancer ◽  
Human Adenovirus ◽  
Adenovirus Type

scholarly journals Canine Adenovirus Vectors: an Alternative for Adenovirus-Mediated Gene Transfer

2000 ◽  
Vol 74 (1) ◽  
pp. 505-512 ◽  
Author(s):  
Eric J. Kremer ◽  
Sylvie Boutin ◽  
Miguel Chillon ◽  
Olivier Danos
Keyword(s):  
Gene Transfer ◽  
Neutralizing Antibodies ◽  
Viral Vectors ◽  
Human Adenovirus ◽  
Adenovirus Type ◽  
Serum Samples ◽  
Humoral And Cellular Immunity ◽  
Adenovirus Vectors ◽  
Adenovirus Type 5

ABSTRACT Preclinical studies have shown that gene transfer following readministration of viral vectors is often inefficient due to the presence of neutralizing antibodies. Vectors derived from ubiquitous human adenoviruses may have limited clinical use because preexisting humoral and cellular immunity is found in 90% of the population. Furthermore, risks associated with the use of human adenovirus vectors, such as the need to immunosuppress or tolerize patients to a potentially debilitating virus, are avoidable if efficient nonhuman adenovirus vectors are feasible. Plasmids containing recombinant canine adenovirus (CAV) vectors from which the E1 region had been deleted were generated and transfected into a CAV E1-transcomplementing cell line. Vector stocks, with titers greater than or equal to those obtained with human adenovirus vectors, were free of detectable levels of replication-competent CAV and had a low particle-to-transduction unit ratio. CAV vectors were replication defective in all cell lines tested, transduced human-derived cells at an efficiency similar to that of a comparable human adenovirus type 5 vector, and are amenable to in vivo use. Importantly, 49 of 50 serum samples from healthy individuals did not contain detectable levels of neutralizing CAV antibodies.

Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response

1997 ◽  
Vol 57 (1-3) ◽  
pp. 19-25 ◽  
Author(s):  
Marielle Christ ◽  
Monika Lusky ◽  
Fabienne Stoeckel ◽  
Dominique Dreyer ◽  
Annick Dieterlé ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Immune Response ◽  
Recombinant Adenovirus ◽  
Host Immune Response ◽  
Adenovirus Vectors
Sign in / Sign up

Export Citation Format

Share Document